PMID: 8949318Aug 1, 1996Paper

Secondary prevention after myocardial infarction; role of beta blockaders

Archives des maladies du coeur et des vaisseaux
A Cohen-SolalO Boudvillain

Abstract

The betablockers are the most important drugs in the secondary prevention after myocardial infarction. Several studies have shown that, in patients without a contraindication to these drugs, betablockers reduce the mortality and recurrence of infarction by about 25%. The best results observed in the subgroup of patients with criteria of severity (previous myocardial infarction or cardiac failure, left ventricular dysfunction, arrhythmias, residual ischaemia, occluded artery or triple vessel disease) has been shown in the APSI and BHAT studies where the reduction in mortality was almost 50% in the subgroup of patients with cardiac failure. The duration of treatment and the role of betablockers with respect to ACE inhibitors are not as clearcut in 1996.

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.